SEATTLE, WA March 11, 2019 — Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing the advanced protein design platform Rosetta announced today that Dr Yifan Song, Cyrus Bio Chief Scientific Officer, will speak at an upcoming meeting of the Boston Area Group for Informatics and Modeling (BAGIM).
Topic: Got Structure? State-of-the-art protein structure prediction with homology modeling
Thursday, March 14th,
Time: 6:00 PM EDT
Venue: Shire – 125 Binney St, Cambridge, MA 02142
computational methods that can be applied during drug discovery
require a protein structure. Ideally, such structures are derived
from experimental approaches such as X-ray, EM or NMR. However,
frequently, an experimental structure of the specific protein of
interest is not available. In such a case we turn to homology
The state-of-the-art for homology model prediction has progressed tremendously over the past two decades. Whereas useful HM models were initially only available in cases where a high-similarity homolog was available in the PDB, it is now often possible to predict such models even when the best homologs have only 15-25% similarity to the sequence whose structure is being predicted. The dramatic improvement in what is possible with HM is due to several factors, including: adoption of methods that can identify suitable low similarity templates on the basis of Markov Models, familial and other deep analysis of sequence space; the ability to incorporate multiple low-similarity templates to broadly span a target sequence; powerful approaches to model building that can handle missing structure due to lack of template, insertions and deletions; and the availability of massive compute power through processor clusters and parallelization. In many cases, the HM models that can be generated are so good—not only in terms of backbone trace, but also in such fine details as hydrogen bonding network, salt bridges, disulphide bonds, etc.—that they are suitable for downstream modeling methods.
We will present the history of HM approaches, culminating in a description of the state-of-the-art Rosetta HM workflow.
For more information on Cyrus Bench, click here.
BAGIM (Boston Area Group for Informatics and Modeling)
BAGIM is an active community of Boston area scientists bringing together people from diverse fields of modeling and informatics to impact life and health sciences. BAGIM strives to create a forum for great scientific discussions covering a wide range of topics including data management, visualization, computational chemistry, drug discovery, protein structure, molecular modeling, structure-based drug design, data mining, software tools, and the sharing of goals and experiences. Our community is made up of participants from academia, government, and/or industry whose goal is to engage in the discussion of science involving a synthesis of theory and technology. Discussions sponsored by BAGIM are targeted to the needs and interests of informatics scientists, computational chemists, medicinal chemists, and statisticians. BAGIM also provides opportunities for networking within these disciplines as well as an arena for the dissemination of information of specific interest to the membership.
Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering Cyrus Bench®, a SaaS platform for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus Bench® is based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington, the most powerful protein engineering software available. Cyrus customers include 10 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.
Cyrus Contact – Lucas Nivon